127 related articles for article (PubMed ID: 8996173)
1. Prognostic factors in early-stage Hodgkin's disease.
Sarris AH
J Clin Oncol; 1997 Jan; 15(1):411-2. PubMed ID: 8996173
[No Abstract] [Full Text] [Related]
2. Stanford V and radiotherapy for Hodgkin's disease.
Portlock CS
Curr Oncol Rep; 2002 Sep; 4(5):413. PubMed ID: 12162915
[No Abstract] [Full Text] [Related]
3. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
[TBL] [Abstract][Full Text] [Related]
4. [Advances in the chemotherapy of malignant lymphoma 1. Chemotherapy of Hodgkin's disease].
Suon SZ
Zhonghua Nei Ke Za Zhi; 1985 Feb; 24(2):117-120, contd. PubMed ID: 2580675
[No Abstract] [Full Text] [Related]
5. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
6. [Primary treatment of early stage Hodgkin's disease].
Molnár Z; Esik O; Illés A
Orv Hetil; 2005 Jan; 146(2):57-61. PubMed ID: 15724953
[TBL] [Abstract][Full Text] [Related]
7. Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy.
Specht L
Cancer Treat Rev; 2004 Aug; 30(5):479-82. PubMed ID: 15245780
[No Abstract] [Full Text] [Related]
8. Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
Johnson PW; Radford JA; Cullen MH; Sydes MR; Stenning SP; Hancock BW
J Clin Oncol; 2006 Jul; 24(20):3309; author reply 3309-10. PubMed ID: 16829655
[No Abstract] [Full Text] [Related]
9. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
Basaran G; Agaoglu F; Basaran M
J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
[No Abstract] [Full Text] [Related]
10. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.
Colonna P; Jais JP; Desablens B; Harousseau JL; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé PY; Guilhot F; Ghandour C; Lejeune F; Andrieu JM
J Clin Oncol; 1996 Jun; 14(6):1928-35. PubMed ID: 8656262
[TBL] [Abstract][Full Text] [Related]
11. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians.
Andrieu JM; Yilmaz U; Colonna P
J Clin Oncol; 1999 Feb; 17(2):730-4. PubMed ID: 10080622
[No Abstract] [Full Text] [Related]
12. Hodgkin's lymphoma: better outcomes with fewer drugs?
Casasnovas O; Coiffier B
Lancet; 2015 Apr; 385(9976):1371-3. PubMed ID: 25539731
[No Abstract] [Full Text] [Related]
13. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
14. [Radiotherapy of Hodgkin's disease].
Patrício MB
Acta Med Port; 1990; 3(1):11-3. PubMed ID: 1692179
[TBL] [Abstract][Full Text] [Related]
15. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
16. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
17. Uncommon presentations of Hodgkin's disease. Case 3. Hodgkin's disease: rectal presentation.
Simpson L; Taylor S; Piotrowski A
J Clin Oncol; 2004 Jan; 22(1):196-8. PubMed ID: 14701784
[No Abstract] [Full Text] [Related]
18. Membranous glomerulonephritis in a patient with Hodgkin's lymphoma in remission.
Sánchez M; Enríquez R; Sirvent AE; Heredia L; Millán I; Amorós F
Nefrologia; 2013; 33(5):745-7. PubMed ID: 24089174
[No Abstract] [Full Text] [Related]
19. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
[TBL] [Abstract][Full Text] [Related]
20. [Controversy regarding the treatment of Hodgkin's disease].
Balwierz W; Armata J
Pol Tyg Lek; 1989 Apr; 44(14):315-9. PubMed ID: 2482966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
